Personalized mRNA Cancer Vaccine Propels Moderna and Merck Shares to New Heights

The market reacted sharply Wednesday as Moderna and Merck announced that a personalized mRNA cancer vaccine halted recurrence in a late‑stage melanoma study.

Personalized mRNA Cancer Vaccine Delivers Breakthrough Results

The experimental drug, intismeran, was paired with Merck’s checkpoint inhibitor Keytruda in a trial involving more than 1,100 high‑risk patients whose tumors had been surgically removed. Combined therapy produced a clinically meaningful improvement over Keytruda alone, according to data slated for presentation at an upcoming oncology conference. Analysts at TD Cowen called the outcome a “landmark moment” for the mRNA platform.

“We may be entering an era where a patient’s tumor profile drives a bespoke treatment,” said William Soliman, CEO of the Accreditation Council for Medical Affairs.

Wall Street responded instantly: Moderna stock jumped ↑ 177% while Merck shares rose ↑ 12.6%. The rally follows a period of volatility after the pandemic era trimmed demand for COVID‑19 shots and saw the Trump administration pull nearly $500 million in federal mRNA funding. Reuters noted that Moderna secured FDA clearance earlier this month for an mRNA‑based seasonal flu vaccine, signaling diversification beyond pandemic‑era products. Investors see the cancer indication as a pathway to restore growth, especially as the safety profile matched earlier studies with no new signals. If the full results confirm the interim readout, the therapy could reach the market as early as next year and be adapted for kidney, bladder and pancreatic cancers, widening the commercial horizon for both companies.